Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
June 27, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, June 27, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
June 03, 2022 14:18 ET
|
Immutep Limited
TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD (N=114)Combination of...
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
June 02, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 27, 2022 08:00 ET
|
Immutep Limited
Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022Improved...
Immutep to Present at Investor Conferences
May 20, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Appoints Leading Oncologists to its Clinical Advisory Board
May 18, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, May 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep Presents New and Significant Data from the AIPAC Study
May 04, 2022 08:00 ET
|
Immutep Limited
Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the...
Immutep Quarterly Activities Report
April 29, 2022 08:00 ET
|
Immutep Limited
New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmarkConstructive feedback...
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
April 28, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
March 30, 2022 08:00 ET
|
Immutep Limited
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory)Encouraging...